Cargando…

Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis

BACKGROUND AND AIM: The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals. METHODS: We analyzed h...

Descripción completa

Detalles Bibliográficos
Autores principales: Adejumo, Adeyinka Charles, Adegbala, Oluwole Muyiwa, Adejumo, Kelechi Lauretta, Bukong, Terence Ndonyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174743/
https://www.ncbi.nlm.nih.gov/pubmed/30345261
http://dx.doi.org/10.1155/2018/9430953
_version_ 1783361332701036544
author Adejumo, Adeyinka Charles
Adegbala, Oluwole Muyiwa
Adejumo, Kelechi Lauretta
Bukong, Terence Ndonyi
author_facet Adejumo, Adeyinka Charles
Adegbala, Oluwole Muyiwa
Adejumo, Kelechi Lauretta
Bukong, Terence Ndonyi
author_sort Adejumo, Adeyinka Charles
collection PubMed
description BACKGROUND AND AIM: The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals. METHODS: We analyzed hospital discharge records of adults (age ≥ 18 years) with a positive HCV diagnosis. We evaluated records from 2007 to 2014 of the Nationwide Inpatient Sample (NIS). We excluded records with other causes of chronic liver diseases (alcohol, hemochromatosis, NAFLD, PBC, HBV, etc.). Of the 188,333 records, we matched cannabis users to nonusers on 1:1 ratio (4,728:4,728), using a propensity-based matching system, with a stringent algorithm. We then used conditional regression models with generalized estimating equations to measure the adjusted prevalence rate ratio (aPRR) for having liver cirrhosis (and its complications), carcinoma, mortality, discharge disposition, and the adjusted mean ratio (aMR) of total hospital cost and length of stay (LOS) [SAS 9.4]. RESULTS: Our study revealed that cannabis users (CUs) had decreased prevalence of liver cirrhosis (aPRR: 0.81[0.72-0.91]), unfavorable discharge disposition (0.87[0.78-0.96]), and lower total health care cost ($39,642[36,220-43,387] versus $45,566[$42,244-$49,150]), compared to noncannabis users (NCUs). However, there was no difference among CUs and NCUs on the incidence of liver carcinoma (0.79[0.55-1.13]), in-hospital mortality (0.84[0.60-1.17]), and LOS (5.58[5.10-6.09] versus 5.66[5.25-6.01]). Among CUs, dependent cannabis use was associated with lower prevalence of liver cirrhosis, compared to nondependent use (0.62[0.41-0.93]). CONCLUSIONS: Our findings suggest that cannabis use is associated with decreased incidence of liver cirrhosis, but no change in mortality nor LOS among HCV patients. These novel observations warrant further molecular mechanistic studies.
format Online
Article
Text
id pubmed-6174743
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-61747432018-10-21 Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis Adejumo, Adeyinka Charles Adegbala, Oluwole Muyiwa Adejumo, Kelechi Lauretta Bukong, Terence Ndonyi Can J Gastroenterol Hepatol Research Article BACKGROUND AND AIM: The effect of cannabis use on chronic liver disease (CLD) from Hepatitis C Virus (HCV) infection, the most common cause of CLD, has been controversial. Here, we investigated the impact of cannabis use on the prevalence of CLD among HCV infected individuals. METHODS: We analyzed hospital discharge records of adults (age ≥ 18 years) with a positive HCV diagnosis. We evaluated records from 2007 to 2014 of the Nationwide Inpatient Sample (NIS). We excluded records with other causes of chronic liver diseases (alcohol, hemochromatosis, NAFLD, PBC, HBV, etc.). Of the 188,333 records, we matched cannabis users to nonusers on 1:1 ratio (4,728:4,728), using a propensity-based matching system, with a stringent algorithm. We then used conditional regression models with generalized estimating equations to measure the adjusted prevalence rate ratio (aPRR) for having liver cirrhosis (and its complications), carcinoma, mortality, discharge disposition, and the adjusted mean ratio (aMR) of total hospital cost and length of stay (LOS) [SAS 9.4]. RESULTS: Our study revealed that cannabis users (CUs) had decreased prevalence of liver cirrhosis (aPRR: 0.81[0.72-0.91]), unfavorable discharge disposition (0.87[0.78-0.96]), and lower total health care cost ($39,642[36,220-43,387] versus $45,566[$42,244-$49,150]), compared to noncannabis users (NCUs). However, there was no difference among CUs and NCUs on the incidence of liver carcinoma (0.79[0.55-1.13]), in-hospital mortality (0.84[0.60-1.17]), and LOS (5.58[5.10-6.09] versus 5.66[5.25-6.01]). Among CUs, dependent cannabis use was associated with lower prevalence of liver cirrhosis, compared to nondependent use (0.62[0.41-0.93]). CONCLUSIONS: Our findings suggest that cannabis use is associated with decreased incidence of liver cirrhosis, but no change in mortality nor LOS among HCV patients. These novel observations warrant further molecular mechanistic studies. Hindawi 2018-09-23 /pmc/articles/PMC6174743/ /pubmed/30345261 http://dx.doi.org/10.1155/2018/9430953 Text en Copyright © 2018 Adeyinka Charles Adejumo et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Adejumo, Adeyinka Charles
Adegbala, Oluwole Muyiwa
Adejumo, Kelechi Lauretta
Bukong, Terence Ndonyi
Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
title Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
title_full Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
title_fullStr Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
title_full_unstemmed Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
title_short Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis
title_sort reduced incidence and better liver disease outcomes among chronic hcv infected patients who consume cannabis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174743/
https://www.ncbi.nlm.nih.gov/pubmed/30345261
http://dx.doi.org/10.1155/2018/9430953
work_keys_str_mv AT adejumoadeyinkacharles reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis
AT adegbalaoluwolemuyiwa reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis
AT adejumokelechilauretta reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis
AT bukongterencendonyi reducedincidenceandbetterliverdiseaseoutcomesamongchronichcvinfectedpatientswhoconsumecannabis